Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126122762 | 12612276 | 2 | F | 20140817 | 20160829 | 20160801 | 20160902 | PER | US-PFIZER INC-3006053 | PFIZER | 17.00 | YR | M | Y | 63.50000 | KG | 20160902 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126122762 | 12612276 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 3000 MG/M2, 5220 MG;OVER 3 HOURS ON DAY 1, FREQ: CYCLICAL | UNK | 11719 | 3000 | MG/M**2 | |||||||
| 126122762 | 12612276 | 2 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 5160 MG, OVER 3 HOURS ON DAY 1, FREQ: CYCLICAL | UNK | 11719 | 5160 | MG | |||||||
| 126122762 | 12612276 | 3 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 5280 MG, OVER 3 HOURS ON DAY 1, FREQ: CYCLICAL | UNK | 11719 | 5280 | MG | |||||||
| 126122762 | 12612276 | 4 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 5220 MG, OVER 3 HOURS ON DAY 1, FREQ: CYCLICAL | UNK | 11719 | 5220 | MG | |||||||
| 126122762 | 12612276 | 5 | SS | EMEND | APREPITANT | 1 | UNK | U | UNK | 0 | |||||||||
| 126122762 | 12612276 | 6 | SS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | 165 MG/M2, ON DAYS 1-21, FREQ: 2 DAY; INTERVAL: 1 | Y | UNK | 0 | 165 | MG/M**2 | ||||||
| 126122762 | 12612276 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | UNK | UNK | 0 | ||||||||||
| 126122762 | 12612276 | 8 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 200 MG/M2, 348 MG;OVER 15-30 MINUTES ON DAYS 1 AND 5, FREQ: CYCLICAL | UNK | 0 | 200 | MG/M**2 | |||||||
| 126122762 | 12612276 | 9 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 352 MG, OVER 15-30 MINUTES ON DAYS 1 AND 5, FREQ: CYCLICAL | UNK | 0 | 352 | MG | |||||||
| 126122762 | 12612276 | 10 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 8.75 MG, ON DAYS 1-5, FREQ: 2 DAY; INTERVAL: 1 | UNK | 0 | 8.75 | MG | |||||||
| 126122762 | 12612276 | 11 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 8.75 MG, ON DAYS 1-5, FREQ: 2 DAY; INTERVAL: 1 | UNK | 0 | 8.75 | MG | |||||||
| 126122762 | 12612276 | 12 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 9 MG, ON DAYS 1-5, FREQ: 2 DAY; INTERVAL: 1 | UNK | 0 | 9 | MG | |||||||
| 126122762 | 12612276 | 13 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | UNK | UNK | 0 | ||||||||||
| 126122762 | 12612276 | 14 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 25 MG/M2, 44 MG;OVER 1-15 MIN ON DAYS 4 AND 5, FREQ: CYCLICAL | UNK | 0 | 25 | MG/M**2 | |||||||
| 126122762 | 12612276 | 15 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 44 MG, 44 MG;OVER 1-15 MIN ON DAYS 4 AND 5, FREQ: CYCLICAL | UNK | 0 | 44 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126122762 | 12612276 | 1 | Anaplastic large cell lymphoma T- and null-cell types |
| 126122762 | 12612276 | 5 | Product used for unknown indication |
| 126122762 | 12612276 | 6 | Anaplastic large cell lymphoma T- and null-cell types |
| 126122762 | 12612276 | 7 | Anaplastic large cell lymphoma T- and null-cell types |
| 126122762 | 12612276 | 10 | Anaplastic large cell lymphoma T- and null-cell types |
| 126122762 | 12612276 | 13 | Anaplastic large cell lymphoma T- and null-cell types |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126122762 | 12612276 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126122762 | 12612276 | Stomatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126122762 | 12612276 | 1 | 20140804 | 20140805 | 0 | |
| 126122762 | 12612276 | 2 | 20141013 | 0 | ||
| 126122762 | 12612276 | 3 | 20140919 | 0 | ||
| 126122762 | 12612276 | 4 | 20140830 | 0 | ||
| 126122762 | 12612276 | 6 | 20140804 | 20140816 | 0 | |
| 126122762 | 12612276 | 7 | 20141103 | 20141107 | 0 | |
| 126122762 | 12612276 | 8 | 20140805 | 20140809 | 0 | |
| 126122762 | 12612276 | 9 | 20140919 | 20140923 | 0 | |
| 126122762 | 12612276 | 10 | 20140804 | 20140808 | 0 | |
| 126122762 | 12612276 | 11 | 20141013 | 20141017 | 0 | |
| 126122762 | 12612276 | 12 | 20140919 | 20140923 | 0 | |
| 126122762 | 12612276 | 13 | 20141106 | 20141107 | 0 | |
| 126122762 | 12612276 | 14 | 20140808 | 20140809 | 0 | |
| 126122762 | 12612276 | 15 | 20140922 | 20140923 | 0 |